. Author manuscript; available in PMC: 2020 May 1.

Published in final edited form as: J Affect Disord. 2019 Feb 26;250:65–70. doi: 10.1016/j.jad.2019.02.063

Table 2.

Relative concentrations of plasma 5-HT at baseline and after 8 weeks SSRI treatment and delta 5-HT (measured as 5-HT levels at week 8 minus 5-HT levels at baseline) in MDD subjects treated with SSRI, divided by responder/non-responder status. Twenty-six subjects (9 non-responders and 17 responders) had 5-HT baseline data but only 23 of these (7 non-responders and 16 responders) had additional 5-HT data at week 8.

	Non-responders	Responders	P-value
5-HT at baseline (mean±SD)	0.78±0.19	1.30±0.62	0.036
5-HT at 8 weeks (mean±SD)	0.52±0.16	0.48±0.21	0.533
Delta 5-HT	−0.31±0.26	−0.88±0.68	0.047